85-6835-01　Mosunetuzumab Biosimilar - Research Grade 5mg　ICH5026

特徴

• 背景：ichorbio’s Mosunetuzumab biosimilar is a bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.

仕様

• サイズ：5mg
• ターゲット：CD3e/CD20
• 交差性：Human
• 精製方法：This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
• 濃度：5mg/ml
• 構成：Sterile, preservative-free, solution in PBS. BSA and Azide free.
• 純度：>95% by SDS-PAGE
• エンドトキシン：≤ 1.0 EU/mg as determined by the LAL method
• 適用：Functional Assays
• データシート：https://ichor.bio/product/Mosunetuzumab-Biosimilar-Research-Grade-ICH5026?action=genpdf&id=81135
• この商品は法規制を確認しておりません。（法規制によって販売できない場合もございます）

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]